Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
BSE
Biostem Technologies
BSEM · NASDAQ · Biological Products, (No Diagnostic Substances) · No 10-K yet
Biostem Technologies (BSEM) · oqro.io/stocks/BSEM · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
Questions about Biostem Technologies insider trading
Have Biostem Technologies insiders bought shares recently?
No open-market purchase by an insider of Biostem Technologies is on record in SEC filings since 2006.
How often do Biostem Technologies insiders buy and sell shares?
Since 2026, Biostem Technologies insiders reported 0 open-market purchases and 1 sale on Forms 4 and 5.
Who is selling Biostem Technologies stock?
In the last 90 days, 1 insider of Biostem Technologies (BSEM) reported 1 open-market sale worth $14K in total on SEC Form 4. The largest seller by value was Jason Matuszewski, with $14K. Many insider sales follow a plan set in advance or cover taxes on stock awards; the filing says what was sold, not the reason.
Do members of Congress trade BSEM?
No trade in Biostem Technologies (BSEM) was disclosed by a member of Congress in the last 12 months.
Where does this data come from?
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
BSEM price and disclosed activity
−84.5% (−$3.46) from Aug 7, 2026 to Nov 20, 2026 · adjusted daily closes
Adjusted close went from $4.09 on Aug 7, 2026 to $0.6351 on Nov 20, 2026 (−84.5%). Disclosed in this range: 0 insider trades, 1 pre-arranged insider sale, 0 Congress trades.
$0$2$3$4$5$6$0.6351
AugSepOctNov
Insider and Congress marks sit on the trade date stated in the filing; solid is a purchase, hollow a sale. A number means several trades too close to tell apart at this range: pick a shorter range or open it for the list. Congress amounts are official ranges; mark size uses the lower bound. Past moves are not a forecast.Show the 1 trade in this range as a list
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Biological Products, (No Diagnostic Substances) company based in Pompano Beach, FL. Listed, but no annual report (10-K) filed yet under this SEC registration.
Last 12 months
Not enough history
Market value
$12.2M
Close of Nov 20, 2026 × shares outstanding (per ADS where it applies)
Short interest: 287K shares sold short (1.5% of shares outstanding), −14.1% vs the previous count, 1.5 days of normal trading to buy them back. FINRA, as of Oct 30, 2026. Short interest history
A Schedule 13G is filed by holders above 5% who say they will not try to influence the company. Index funds and large asset managers file most of them.
A Schedule 13G is filed by holders above 5% who say they will not try to influence the company. Index funds and large asset managers file most of them.
A Schedule 13G is filed by holders above 5% who say they will not try to influence the company. Index funds and large asset managers file most of them.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Insider buying and selling since 2026
Insiders of Biostem Technologies reported 0 open-market purchases and 1 sale since 2026; no open-market purchase.
Year
Bought
Sold
2026
—
$14K1×1 trade
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
Latest results: quarter ending Sep 30, 2026
Revenue
$7.64M
−27.0% vs the same quarter a year earlier
Free cash flow, last 12 months
−$8.82M
This quarter −$8.82M, a year earlier −$4.8M
Net cash
$971K
Debt $0, cash $971K, at Sep 30, 2026
Net income, last 12 months
—
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Nov 12, 2026.
Since Aug 7, 2026, BSEM is down 84.5% and the index fund is down 10.8%: 74 points behind the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much BSEM moves
A usual day
±5.3%Half of the sessions moved less than this, half moved more.
Daily range (ATR 14)
39.9%How far the price usually travels in a session, the gap from the day before included. Wilder's 14-session average.
Largest one-day fall
−26.3%Oct 19, 2026
Largest one-day rise
+41.3%Nov 11, 2026
Deepest fall of the year
−86.6%From the close of Sep 18, 2026 to Nov 20, 2026.
Days of 5% or more
40Out of 74 sessions, in either direction.
End-of-day prices. These figures describe the past year and say nothing about what comes next.
Where the revenue comes from
Latest quarter
The three months Jul 1, 2026 to Sep 30, 2026, compared with the same quarter a year earlier, from the quarterly report filed Nov 12, 2026. Quarterly reports are not audited. Read the filing
By product or service
Hospital$6.83M89%
$0 the same quarter a year earlier
Physician office$810K11%
−92% on the same quarter a year earlier ($10.4M)
Other$00.0%
$60K the same quarter a year earlier
Total revenue$7.64M−27%
Source: SEC EDGAR, Form 10-Q filed Nov 12, 2026. Revenue lines are the figures the company tags in its filing; OQRO shows a split only when its lines add up to the reported total revenue. Not investment advice.
Last 30 days
Written by software from the filings listed below · Nov 21, 2026
Insiders. In the 30 days to Nov 21, 2026, insiders of Biostem Technologies filed 0 open-market purchases and 1 open-market sale (about $14K, in 1 filing, by 1 person). One Form 4 can list many transactions. In the 30 days before that, they filed 0 open-market purchases and 0 open-market sales. (Biostem Technologies on OQRO)
Funds and stakes. Jason Matuszewski now owns 17.4% of BSEM as a passive investor (filed Nov 10, 2026). Andrew Van Vurst now owns 18.4% of BSEM as a passive investor (filed Nov 10, 2026).
Contracts, lobbying and filings. FINRA short interest for BSEM on the settlement date of Oct 30, 2026 was 286,950 shares (-14.05% on the previous report), about 1.53 days of average volume.
Company reports, price and press. Biostem Technologies filed a Form 8-K on Nov 12, 2026 (Item 2.02) that OQRO classes as: reported its results. The press release filed with it is titled: "BioStem Technologies Reports Third Quarter 2026 Financial Results; Grows Hospital Revenue for Second Consecutive Quarter as Customers Expand Use of Portfolio"
Things to keep in mind. These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why. A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade. An 8-K item says what the company reported, not what it means for the share price.
Facts used for this text
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Insiders
In the 30 days to Nov 21, 2026, insiders of Biostem Technologies filed 0 open-market purchases and 1 open-market sale (about $14K, in 1 filing, by 1 person). One Form 4 can list many transactions.
In the 30 days before that, they filed 0 open-market purchases and 0 open-market sales.
The largest sale: Jason Matuszewski, Chief Executive Officer, about $14K, filed Nov 19, 2026.
Funds and stakes
Jason Matuszewski now owns 17.4% of BSEM as a passive investor (filed Nov 10, 2026).
Andrew Van Vurst now owns 18.4% of BSEM as a passive investor (filed Nov 10, 2026).
Contracts, lobbying and filings
FINRA short interest for BSEM on the settlement date of Oct 30, 2026 was 286,950 shares (-14.05% on the previous report), about 1.53 days of average volume.
Company reports, price and press
Biostem Technologies filed a Form 8-K on Nov 12, 2026 (Item 2.02) that OQRO classes as: reported its results.
The press release filed with it is titled: "BioStem Technologies Reports Third Quarter 2026 Financial Results; Grows Hospital Revenue for Second Consecutive Quarter as Customers Expand Use of Portfolio"
Its announcing sentence reads: "BioStem Technologies, Inc. (Nasdaq: BSEM) ("BioStem" or the "Company"), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today reported financial results for the third quarter ended September 30, 2026 an..."
Press coverage listed by Finnhub: "BioStem Technologies to Host Third Quarter 2026 Financial Results Conference Call on November 12, 2026" (Yahoo, Oct 29, 2026).
BSEM closed at $0.6351 on Nov 20, 2026, the last session on or before the end of the period.
From Oct 21, 2026 to Nov 20, 2026, the close moved from $1.68 to $0.6351, a change of −62.2%.
Things to keep in mind
These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why.
A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade.
An 8-K item says what the company reported, not what it means for the share price.
Headlines are listed as published by the outlets; OQRO has not checked them and does not summarise articles.
Share price moves are listed as context only; the filing does not explain them and other news can move a price.
This describes public filings. It is not investment advice.
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Funds and stakes. Jason Matuszewski now owns 17.4% of BSEM as a passive investor (filed Nov 10, 2026). Andrew Van Vurst now owns 18.4% of BSEM as a passive investor (filed Nov 10, 2026). (Biostem Technologies on OQRO)
Contracts, lobbying and filings. FINRA short interest for BSEM on the settlement date of Oct 30, 2026 was 286,950 shares (-14.05% on the previous report), about 1.53 days of average volume.
Company reports, price and press. Biostem Technologies filed a Form 8-K on Nov 12, 2026 (Item 2.02) that OQRO classes as: reported its results. Biostem Technologies filed a Form 8-K on Sep 30, 2026 (Items 1.01, 3.02, 7.01, 8.01) that OQRO classes as: signed an important agreement, and sold new shares without registering them (and 2 more items).
Deals. Biostem Technologies is the buyer of BioTissue Holdings, Inc., a deal of about $10M; status: announced, first on record Oct 1, 2026.
Things to keep in mind. These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why. A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade. An 8-K item says what the company reported, not what it means for the share price.
Facts used for this text
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Funds and stakes
Jason Matuszewski now owns 17.4% of BSEM as a passive investor (filed Nov 10, 2026).
Andrew Van Vurst now owns 18.4% of BSEM as a passive investor (filed Nov 10, 2026).
Contracts, lobbying and filings
FINRA short interest for BSEM on the settlement date of Oct 30, 2026 was 286,950 shares (-14.05% on the previous report), about 1.53 days of average volume.
Company reports, price and press
Biostem Technologies filed a Form 8-K on Nov 12, 2026 (Item 2.02) that OQRO classes as: reported its results.
Biostem Technologies filed a Form 8-K on Sep 30, 2026 (Items 1.01, 3.02, 7.01, 8.01) that OQRO classes as: signed an important agreement, and sold new shares without registering them (and 2 more items).
Biostem Technologies filed a Form 8-K on Sep 18, 2026 (Items 1.01, 3.02, 7.01) that OQRO classes as: signed an important agreement, and sold new shares without registering them (and 1 more item).
BSEM closed at $0.8182 on Nov 18, 2026, the last session on or before the end of the period.
From Oct 19, 2026 to Nov 18, 2026, the close moved from $1.54 to $0.8182, a change of −46.9%.
Deals
Biostem Technologies is the buyer of BioTissue Holdings, Inc., a deal of about $10M; status: announced, first on record Oct 1, 2026.
Things to keep in mind
These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why.
A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade.
An 8-K item says what the company reported, not what it means for the share price.
Share price moves are listed as context only; the filing does not explain them and other news can move a price.
This describes public filings. It is not investment advice.
Off-exchange trading: 54.6% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (12.3% on ATS, 42.3% with other brokers), above its 10-week average of 50.9%. Weeks of Sep 21 to Oct 16, 2026.
Week of Aug 10ATSOther off-exchangeFull height = all shares tradedWeek of Oct 12
Largest ATS: BIDS ATS (22.4%), UBS ATS (11.1%), INTELLIGENT CROSS LLC (10.9%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.